Myovant conference call tomorrow on late-stage study of relugolix in prostate cancer
The output is 2 because the tweet is talking about a late-stage study of a drug that could potentially be used to treat prostate cancer. Since this is a positive development in terms of finding a way to treat prostate cancer, it would con